CuraSen Therapeutics has commenced its Phase IIa proof-of-concept trial of CuraAX (CST-3056) with dosing of the first patient ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a critical study ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Tvardi Therapeutics, Inc. (NASDAQ: TVRD) resulting from ...

Oral and inhaled biologics are gaining R&D investment due to patient acceptance and potential for home administration, with ...

Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

SCYNEXIS Inc. (NASDAQ: SCYX) is one of the best long term penny stocks with huge upside potential. On September 30, SCYNEXIS ...

The peptide lab is designed to produce a range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates.

The Phase III placebo-controlled, randomised, double-blind study is evaluating ADX-324's efficacy in adults with HAE.

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and ...

Title: Identification of CGT1263, a Potent KRAS Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS Session Date and Time: Poster Session B, Friday, October 24, 2025 – 12:30 p.m. – 4:00 p.m.